What are the terms of payment?

The accepted terms of payment are LC (Letter of Credit) and T/T (Telegraphic Transfer).

What is the average lead time for orders?

The peak season lead time is one month.

What is the drug approval number?

The Drug Reg./Approval No. is 20030477.

Citicoline and Glucose Injection GMP Manufacturer

Name: Citicoline and Glucose Injection GMP Manufacturer
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 740739362

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.50-1.50

20,000 Pieces

Sample price:US$1.00/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Injection

Model NO.

100ml 200ml

Suitable for

Elderly, Adult

State

Liquid

Shape

Injection

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

20030477

Product Line

GMP Approval

Transport Package

Carton

Specification

100ml 200ml

Trademark

SHIMEN

Origin

Hebei

HS Code

3004909099

Production Capacity

1000000

Key features

GMP Certified Manufacturer: Production strictly follows GMP requirements with full automation control.

70-Year Industry Experience: Leading manufacturer with a business history of seventy years in pharmaceuticals.

Advanced Production Technology: Integrates world-leading equipment for international advanced level production.

Global Market Reach: Products exported to over 80 countries across Asia, Americas, Europe, and Africa.

Top 100 Enterprise Status: Recognized as one of China's top 100 pharmaceutical industry enterprises.

Comprehensive Product Range: Specializes in IV solutions, large volume injections, tablets, and capsules.

Strong R&D Capability: Powerful team with achievements in scientific research and innovation projects.

Therapeutic Efficacy: Increases cerebral blood flow and promotes brain function recovery.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤9.90hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.